Interpretation of immune function status assessment in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 edition)

doi:10.19982/j.issn.1000-6621.20220421

Abstract

Abstract:

More and more clinical evidence showed that tuberculosis is not only an infectious disease, but also an immune disease. Many patients with active tuberculosis have the low immune function, so it is important and necessary to evaluate their immune function status, which can provide a basis for clinical immune intervention. Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 edition) published in Issue 1 of 2022 in the Chinese Journal of Antituberculosis, provides recommendations for the evaluation of immune function status and immunotherapy in tuberculosis patients, and forms a consensus. This interpretation mainly focuses on the assessment of immune function status, introduces more new progress of immune evaluation beyond the consensus for the readers, and enriches readers’ understanding of immune function assessment in tuberculosis patients.

Key words: Tuberculosis, Immunoassay, Consensus development conferences as topic

CLC Number:

Xue Yong, Wu Xueqiong. Interpretation of immune function status assessment in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 edition)[J]. Chinese Journal of Antituberculosis, 2023, 45(2): 134-138. doi: 10.19982/j.issn.1000-6621.20220421

References 26

[1]	中国人民解放军总医院第八医学中心全军结核病研究所/全军结核病防治重点实验室/结核病诊疗新技术北京市重点实验室, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础和临床学部. 活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版). 中国防痨杂志, 2022, 44(1): 9-27. doi:10.19982/j.issn.1000-6621.20210680. doi: 10.19982/j.issn.1000-6621.20210680
[2]	Nakao M, Muramatsu H, Arakawa S, et al. Immunonutritional status and pulmonary cavitation in patient with tuberculosis: A revisit with an assessment of neutrophil/lymphocyte ratio. Respir Investig, 2019, 57(1): 60-66. doi:10.1016/j.resinv.2018.08.007. doi: 10.1016/j.resinv.2018.08.007 URL
[3]	Jeon YL, Lee WI, Kang SY, et al. Neutrophil-to-Monocyte-Plus-Lymphocyte Ratio as a Potential Marker for Discriminating Pulmonary Tuberculosis from Nontuberculosis Infectious Lung Diseases. Lab Med, 2019, 50(3): 286-291. doi:10.1093/labmed/lmy083. doi: 10.1093/labmed/lmy083 pmid: 30753566
[4]	《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础专业和临床专业学术部. 结核病患者外周血淋巴细胞亚群检测及临床应用专家共识. 中国防痨杂志, 2020, 42(10): 1009-1016. doi:10.3969/j.issn.1000-6621.2020.10.001. doi: 10.3969/j.issn.1000-6621.2020.10.001
[5]	Hally KE, Ferrer-Font L, Pilkington KR, et al. OMIP 083: A 21-marker 18-color flow cytometry panel for in-depth phenotyping of human peripheral monocytes. Cytometry A, 2022, 101(5): 374-379. doi:10.1002/cyto.a.24545. doi: 10.1002/cyto.a.24545 URL
[6]	Castaño D, García LF, Rojas M. Increased frequency and cell death of CD16⁺ monocytes with Mycobacterium tuberculosis infection. Tuberculosis (Edinb), 2011, 91(5): 348-360. doi:10.1016/j.tube.2011.04.002. doi: 10.1016/j.tube.2011.04.002 URL
[7]	曹雪涛, 姚智, 熊思东, 等. 医学免疫学. 7版. 北京: 人民卫生出版社, 2018: 109-118.
[8]	Estévez O, Anibarro L, Garet E, et al. Multi-parameter flow cytometry immunophenotyping distinguishes different stages of tuberculosis infection. J Infect, 2020, 81(1): 57-71. doi:10.1016/j.jinf.2020.03.064. doi: S0163-4453(20)30218-8 pmid: 32330526
[9]	Ndishimye P, Zakham F, Musanabaganwa C, et al. CD4⁺ regulatory T cells and CD4⁺ activated T cells in new active and relapse tuberculosis. Cell Mol Biol (Noisy-le-grand), 2019, 65(8): 18-22.
[10]	Qin S, Chen R, Jiang YJ, et al. Multifunctional T cell response in active pulmonary tuberculosis patients. Int Immunopharmacol, 2021, 99: 107898. doi:10.1016/j.intimp.2021.107898. doi: 10.1016/j.intimp.2021.107898 URL
[11]	Okada R, Kondo T, Matsuki F, et al. Phenotypic classification of human CD4⁺ T cell subsets and their differentiation. Int Immunol, 2008, 20(9): 1189-1199. doi:10.1093/intimm/dxn075. doi: 10.1093/intimm/dxn075 pmid: 18635582
[12]	Harari A, Dutoit V, Cellerai C, et al. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev, 2006, 211: 236-254. doi:10.1111/j.0105-2896.2006.00395.x. doi: 10.1111/j.0105-2896.2006.00395.x pmid: 16824132
[13]	Priyanto H, Chua E, Hutchinson P, et al. A decrease in PPD specific CD4 T cell CD38 and HLA-DR expression in pulmonary tuberculosis patients after 8 weeks of therapy correlates with successful anti-tuberculosis treatment. J Clin Tuberc Other Mycobact Dis, 2021, 22: 100214. doi:10.1016/j.jctube.2021.100214. doi: 10.1016/j.jctube.2021.100214
[14]	Luo Y, Xue Y, Mao L, et al. Activation Phenotype of Mycobacterium tuberculosis-Specific CD4⁺ T Cells Promoting the Discrimination Between Active Tuberculosis and Latent Tuberculosis Infection. Front Immunol, 2021, 12: 721013. doi:10.3389/fimmu.2021.721013. doi: 10.3389/fimmu.2021.721013 URL
[15]	Adekambi T, Ibegbu CC, Cagle S, et al. Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. J Clin Invest, 2015, 125(5): 1827-1838. doi:10.1172/JCI77990. doi: 10.1172/JCI77990 pmid: 25822019
[16]	Luo Y, Xue Y, Tang GX, et al. Lymphocyte-Related Immunological Indicators for Stratifying Mycobacterium tuberculosis Infection. Front Immunol, 2021, 12: 658843. doi:10.3389/fimmu.2021.658843. doi: 10.3389/fimmu.2021.658843 URL
[17]	Kiran B, Cagatay T, Clark P, et al. Can immune parameters be used as predictors to distinguish between pulmonary multidrug-resistant and drug-sensitive tuberculosis? Arch Med Sci, 2010, 6(1): 77-82. doi:10.5114/aoms.2010.13511. doi: 10.5114/aoms.2010.13511 pmid: 22371724
[18]	Bernal-Fernandez G, Espinosa-Cueto P, Leyva-Meza R, et al. Decreased expression of T-cell costimulatory molecule CD 28 on CD4 and CD8 T cells of mexican patients with pulmonary tuberculosis. Tuberc Res Treat, 2010, 2010: 517547. doi:10.1155/2010/517547. doi: 10.1155/2010/517547
[19]	Vickers MA, Darboe F, Muefong CN, et al. Monitoring Anti-tuberculosis Treatment Response Using Analysis of Whole Blood Mycobacterium tuberculosis Specific T Cell Activation and Functional Markers. Front Immunol, 2020, 11: 572620. doi:10.3389/fimmu.2020.572620. doi: 10.3389/fimmu.2020.572620 URL
[20]	Wang X, Liang KD, Zhang JA, et al. Increased B cell activating factor is associated with B cell class switching in patients with tuberculous pleural effusion. Mol Med Rep, 2018, 18(2): 1704-1709. doi:10.3892/mmr.2018.9073. doi: 10.3892/mmr.2018.9073 pmid: 29845274
[21]	Morais-Papini TF, Coelho-Dos-Reis JGA, Wendling APB, et al. Systemic Immunological changes in patients with distinct clinical outcomes during Mycobacterium tuberculosis infection. Immunobiology, 2017, 222(11): 1014-1024. doi:10.1016/j.imbio.2017.05.016. doi: S0171-2985(17)30099-2 pmid: 28619539
[22]	Jean Bosco M, Wei M, Hou H, et al. The exhausted CD4⁺CXCR5⁺ T cells involve the pathogenesis of human tuberculosis disease. Int J Infect Dis, 2018, 74: 1-9. doi:10.1016/j.ijid.2018.06.011. doi: 10.1016/j.ijid.2018.06.011 URL
[23]	An HR, Bai XJ, Liang JQ, et al. The relationship between absolute counts of lymphocyte subsets and clinical features in patients with pulmonary tuberculosis. Clin Respir J, 2022, 16(5): 369-379. doi:10.1111/crj.13490. doi: 10.1111/crj.13490 URL
[24]	Gao XF, Yang ZW, Li J. Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a syste-matic review. Int J Infect Dis, 2011, 15(9): e594-e600. doi:10.1016/j.ijid.2011.05.002. doi: 10.1016/j.ijid.2011.05.002
[25]	Seneviratne SL, Doffinger R, Macfarlane J, et al. Disseminated Mycobacterium tuberculosis infection due to interferon gamma deficiency. Response to replacement therapy. Thorax, 2007, 62(1): 97-99. doi:10.1136/thx.2005.051649. doi: 10.1136/thx.2005.051649 pmid: 17189534
[26]	Zhang R, Xi X, Wang C, et al. Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis. PLoS One, 2018, 13(7): e0201025. doi:10.1371/journal.pone.0201025. doi: 10.1371/journal.pone.0201025